Governments race to regulate AI in medicine as stakes climb higher

When your doctor’s diagnosis comes from an algorithm, the question of who regulates that algorithm suddenly matters a lot. Governments on both sides of the Atlantic are now scrambling to answer it. The UK’s National Commission into the Regulation of AI in Healthcare dropped 44 recommendations on September 9-10, 2026, calling for a fundamental overhaul of how AI-powered medical devices get approved and monitored. The US Food and Drug Administration released its own discussion paper on generative AI medical devices in August. And the European Union’s AI Act is rolling out high-risk classifications for medical AI systems over the next two years. The UK wants to tear up the old approval model The UK commission, established by the Medicines and Healthcare products Regulatory Agency (MHRA) in September 2025 and led by NHS doctors, is proposing something genuinely different. Instead of the traditional approve-it-once-and-forget-it model, the commission wants a lifecycle-based, risk-proportionate system. One of the more interesting proposals is what the commission calls “L-plate” authorizations, essentially staged approvals where AI systems operate under supervision before earning full cle...